Condition (MeSH)
Giant Cell Tumors
ClinicalTrials.gov lists 55 trials for Giant Cell Tumors or a narrower condition beneath it. Daiichi Sankyo has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 55 trials are tagged with Giant Cell Tumors itself; the rest are tagged with a narrower condition beneath it.
When did Giant Cell Tumors trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 6 |
| 2022 | 1 |
| 2021 | 6 |
| 2020 | 6 |
| 2019 | 3 |
| 2018 | 4 |
| 2017 | 2 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 33 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Giant Cell Tumors trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 4 |
| Phase 2 | 17 |
| Phase 3 | 8 |
| Phase 4 | 5 |
| Not applicable | 1 |
| Observational | 15 |
How many Giant Cell Tumors trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 13 |
| Active, not recruiting | 7 |
| Completed | 24 |
| Terminated | 5 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Giant Cell Tumors trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Daiichi Sankyo | 6 |
| Amgen | 4 |
| AmMax Bio, Inc. | 3 |
| Deciphera Pharmaceuticals, LLC | 3 |
| Shanghai JMT-Bio Inc. | 3 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Giant Cell Tumors? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| DENOSUMAB | 8 |
| Pexidartinib | 6 |
| Pimicotinib | 4 |
| Vimseltinib | 3 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| AMB-05X | 3 |
| Nilotinib Pill | 2 |
| acid Zoledronic | 2 |
| Indocyanine Green dye | 2 |
| Autologous Tumor Infiltrating Lymphocytes LN-145-S1 | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Giant Cell Tumors trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dyspnea | 34 | 1 |
| Pleural effusion | 30 | 1 |
| Osteonecrosis of jaw | 26 | 2 |
| Nausea | 23 | 4 |
| Vomiting | 21 | 4 |
Showing 5 of 10 adverse events.
Which publications cover Giant Cell Tumors? (19)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Indocyanine green fluorescence imaging may detect tumour residuals during surgery for bone and soft-tissue tumours. | The bone & joint journal | 2023 | Yes |
| The Efficacy of Radiofrequency Ablation for Bone Tumors Unsuitable for Radical Excision. | Clinics in orthopedic surgery | 2021 | Yes |
| CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. | The Lancet. Oncology | 2015 | Yes |
| Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. | The New England journal of medicine | 2015 | Yes |
| Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). | Annals of oncology : official journal of the European Society for Medical Oncology | 2008 | Yes |
Showing 5 of 19 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.